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Abstract
Background
Chronic Fatigue Syndrome (CFS/ME) is a complex multisystem disease of unknown aetiol-
ogy which causes debilitating symptoms in up to 1% of the global population. Although a
large cohort of genes have been shown to exhibit altered expression in CFS/ME patients, it
is currently unknown whether microRNA (miRNA) molecules which regulate gene transla-
tion contribute to disease pathogenesis. We hypothesized that changes in microRNA
expression in patient leukocytes contribute to CFS/ME pathology, and may therefore repre-
sent useful diagnostic biomarkers that can be detected in the peripheral blood of CFS/ME
patients.
Methods
miRNA expression in peripheral blood mononuclear cells (PBMC) from CFS/ME patients
and healthy controls was analysed using the Ambion Bioarray V1. miRNA demonstrating
differential expression were validated by qRT-PCR and then replicated in fractionated blood
leukocyte subsets from an independent patient cohort. The CFS/ME associated miRNA
identified by these experiments were then transfected into primary NK cells and gene
expression analyses conducted to identify their gene targets.
Results
Microarray analysis identified differential expression of 34 miRNA, all of which were up-reg-
ulated. Four of the 34 miRNA had confirmed expression changes by qRT-PCR.
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Fractionating PBMC samples by cell type from an independent patient cohort identified
changes in miRNA expression in NK-cells, B-cells and monocytes with the most significant
abnormalities occurring in NK cells. Transfecting primary NK cells with hsa-miR-99b or hsa-
miR-330-3p, resulted in gene expression changes consistent with NK cell activation but
diminished cytotoxicity, suggesting that defective NK cell function contributes to CFS/ME
pathology.
Conclusion
This study demonstrates altered microRNA expression in the peripheral blood mononuclear
cells of CFS/ME patients, which are potential diagnostic biomarkers. The greatest degree of
miRNA deregulation was identified in NK cells with targets consistent with cellular activation
and altered effector function.
Introduction
Chronic Fatigue Syndrome / Myalgic Encephalomyelitis (CFS/ME) is characterised by severe
and debilitating fatigue lasting 6 months with associated muscular, infectious and neuropsychi-
atric symptoms. CFS/ME has a world prevalence of 0.4–1% with 240,000 UK and 800,000 US
affected individuals [1, 2]. Currently there is no accepted diagnostic test or diagnostic biological
marker for CFS/ME. The clinical diagnosis of CFS/ME is based on a process of exclusion cul-
minating in the fulfilment of a set of clinical criteria after six months of illness [3–5]. Thus
there is a real clinical need to identify a diagnostic biomarker in this disease. A number of stud-
ies have looked for biomarkers in CFS/ME in either the mRNA [6–8] or serum [9] of CFS/ME
patients, with limited success. Ongoing research has focused on characterising immune defects
in CFS/ME as onset of symptoms is frequently preceded by evidence of immune insult [10].
Alterations in populations and numbers of leucocytes in the peripheral blood of patients have
been confirmed [11, 12]. Recent research has identified significant immune deregulation in
CFS/ME with altered cytokine expression and reduction in the killing capacity of cytotoxic
cells the most consistent findings [11, 13, 14]. Changes in mRNA expression in the peripheral
blood have been well documented in CFS/ME, with a predominant bias towards genes involved
in: immune function, apoptosis, transcription, translation and virus infection [7, 8, 15–26].
mRNA gene expression studies have also been successful in defining subtypes of CFS/ME, each
with a distinct symptom profile [24]. One group of molecules that have a role in regulating the
translation of mRNA and have yet to be systematically surveyed in blood cells of CFS/ME sub-
jects are microRNA (miRNA).
miRNA are a group of small non-coding RNA (~23nt) which function to regulate the trans-
lation of mRNA post transcription via direct degradation of mRNA transcripts or repression of
translation. miRNA are crucial for maintaining normal haematopoiesis and moderating
immune signalling cascades [27, 28] suggesting their utility as biomarkers in this disease.
In this study, we screened peripheral blood samples derived from patients with an estab-
lished clinical diagnosis of CFS/ME compared to age matched healthy controls and identified
deregulation of miRNA with functions consistent with published mRNA expression changes in
CFS/ME. To determine in which cell type these changes in miRNA expression were occurring,
deregulation was confirmed in an independent patient cohort of fractionated peripheral blood
cells. Expression of hsa-miR-99b and hsa-miR-330-3p in natural killer cells exhibited the
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greatest degree of over expression. When characterised in NK cells, these miRNA targeted
genes involved in activation, effector function, actin cytoskeleton and motility. This work sup-
ports and expands the current concepts of immune deregulation in CFS/ME and identifies
putative biomarkers for disease diagnosis.
Results
Thirty-four miRNA demonstrate increased expression in CFS/ME
peripheral blood
To identify miRNA differentially expressed in CFS/ME, RNA was extracted from peripheral
blood mononuclear cell (PBMC) samples and screened using Ambion Bioarray microarrays
(version 1 targeting 385 miRNA sequences). Fifteen CFS/ME subjects meeting the Fukuda
diagnostic criteria (N = 15) and age and sex matched controls (N = 30) were analysed (cohort
characteristics summarized in S1 Table). A class comparison identified thirty four miRNA
exhibiting differential expression greater than 1.5 fold change [false discovery rate (FDR) 0.05]
(Fig 1 panel A, Full list S2 Table).
Unsupervised cluster analysis (Fig 2) of the microarray data grouped the samples into two
clusters. This analysis failed to fully resolve the CFS/ME and control samples into separate clus-
ters. Approximately half the control samples (N = 14) group with four CFS/ME samples with
low global miRNA expression. The remaining controls clustered with the majority of CFS/ME
subjects demonstrating higher miRNA expression across the majority of miRNA analysed. The
level of homogeneity between samples is high with an average correlation coefficient of 0.922
(+/- 0.068 SD) which may contribute to the incomplete resolution of the samples by clustering.
Interrogating this data by miRNA demonstrated the robustness of the expression data with
miRNA known to be expressed in clusters grouped by expression in the analysis. This includes
the let-7 miRNA cluster consisting of eight related miRNA [29] and miR-103 and 107 which
have related functions and similar expression patterns [30]. We looked for correlation between
miRNA gene expression data and clinical questionnaire scores from five general health ques-
tionnaires, however, none was found. This data demonstrates that miRNA were deregulated in
the peripheral blood of CFS/ME patients and that levels of these miRNA were independent of
symptom severity.
Significant up regulation of microRNAs hsa-miR-99b, hsa-miR-330-3p,
hsa-miR-126 and hsa-miR-30c in CFS/ME blood samples
The miRNA expression changes of 29 out of the 34 miRNA identified in the array screen were
validated in the same samples by Taqman quantitative PCR. Five miRNA (ambi-miR-7058,
hsa-miR-331, mmu-miR-140-AS, mmu-miR-409, rno-miR-151-AS) were not included as Taq-
man assays were unavailable. Four of the 29 miRNA (hsa-miR-99b, hsa-miR-330-3p, hsa-miR-
30c & hsa-miR-126) exhibited significant differential expression 1.5 fold between the CFS
and control cohorts at P0.05, using an additional statistical exclusion filter rejecting datasets
if the 95% confidence interval for the fold change ratio included one (i.e. the probability of no
change) (Fig 1 Panel B).
Four miRNA have potential to be effective biomarkers in CFS/ME by
ROC analysis
To identify if the four confirmed differentially expressed miRNA (hsa-miR-99b, hsa-miR-330-
3p, hsa-miR-126, hsa-miR-30c) could act as biomarkers for CFS/ME diagnosis, Receiver Oper-
ating Characteristics (ROC) were carried out for each set of RQ values for each miRNA. This
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Fig 1. Statistically significant differentially expressedmiRNA in CFS/ME analysed by microarray (A), validation by qPCR (B) boxes display
interquartile range (25%-75%), error bars indicate minimum andmaximum values *P>0.05.
doi:10.1371/journal.pone.0150904.g001
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Fig 2. Unsupervised cluster analysis of miRNAmicroarray data. Clustering normalised miRNA
expression values, present in50% of samples by gene and sample, data is correlated by Euclidean
distance using an average linkage to define the linkage tree (Performed using cluster V3.0 visualised in tree
view). Each column represents one sample, each row a miRNA. miRNA expression is represented in red for
high expression, green for low expression and grey for data excluded at normalisation.
doi:10.1371/journal.pone.0150904.g002
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statistic describes the ability of a variable to classify any sample into two groups and has previ-
ously been used to define serum biomarkers in CFS/ME [9, 31]. The four miRNA tested had
area under the curve (AUC) values ranging from 0.71 to 0.78. All four miRNA tested exhibited
statistically significant differences in AUC compared to a hypothesis of random chance
(AUC = 0.5). Hsa-miR-330-3p was identified by this analysis as the mostly likely variable to
differentiate CFS/ME patients from controls, demonstrating the lowest P-value and the greatest
AUC (Fig 3). These data demonstrates that within the confines of this study these four miRNA
were diagnostic biomarkers of CFS/ME.
Hsa-miR-99b is significantly up regulated in NK cells in CFS/ME patients
To examine whether the miRNA changes observed in whole blood samples were specific to a
particular PBMC population, 20 patients and 20 age and sex matched healthy volunteers were
recruited using the same clinical diagnostic criteria as in the previous study. Blood samples
were taken and PBMCs isolated. Constituent cells were fractionated using sequential rounds of
positive selection using CD14+ (monocytes), CD19+ (B-cells), CD56+ (NK cells) and CD3+
(T-cells) microbeads. Flow cytometry of the fractionated populations demonstrated an average
purity of 96.9% (+/- 2.1% SD) for monocytes, 88.9% (+/- 7.6% SD) for NK cells, 84.4% (+/-
8.8% SD) for B-cells and 91.2% (+/- 5.3% SD) for T-cells. Absolute cell counts post fraction-
ation failed to show statistically significant differences between population groups for the four
leukocyte subsets interrogated (data not shown).
The four miRNA that were confirmed to be differentially expressed by both the array and
qRT-PCR experiments (hsa-miR-99b, hsa-miR-330-3p, hsa-miR-126, hsa-miR-30c) were
interrogated in RNA extracted from these 4 major blood leukocyte populations. Three of the
miRNA tested (hsa-miR-99b, hsa-miR-126 and hsa-miR-330-3p) demonstrated significant up-
regulated expression in one or more PBMC subset in the CFS/ME population. Hsa-miR-30c
exhibited no significant difference in expression between CFS/ME and control cell populations.
The greatest difference in expression between population groups was in the expression of hsa-
miR-99b in NK cells which demonstrated a 2 fold increase in CFS/ME samples. This miRNA
was also up regulated 1.6 fold in B-cells, but remained unchanged in T-cells and monocytes.
Hsa-miR-330-3p was also significantly up regulated in NK cells but to a much lower degree,
exhibiting a 1.3 fold increase. Hsa-miR-126 was up regulated in monocytes by 1.45 fold in the
CFS/ME group (Fig 4). These data identified that the CFS/ME-associated dysregulation of
miRNA is leukocyte population specific, and suggest that dysfunction of blood B-cell, NK cells
and monocytes contribute to disease pathology.
Hsa-miR-99b and hsa-miR-330-3p regulate pathways contributing to NK
cell activation and effector function
To identify the gene targets of hsa-miR-99b and hsa-miR-330-3p in NK cells, precursor
miRNA were transfected into NK cells isolated by negative magnetic bead selection from buffy
coat derived PBMCs. NK cell purity post enrichment was 89.6% (0.7 +/- SD) determined by
flow cytometry (data not shown).
Transfection of primary NK cells with pre-miR-99b compared with transfected nonsense
control identified 37 genes with differential expression passing the inclusion criteria (P0.05
fold change1.5). Twenty one genes exhibited down regulation, with fold changes between 1.5
and 1.8. Sixteen genes demonstrated increased expression between 1.5 and 2.6. Interferon
gamma (IFN-Y), which is a key mediator of NK cell activation, was the most highly induced
gene (2.6 fold). Granzyme B (GZMB), which encodes a component of the cytotoxic granules
that NK cells release upon recognition of target cells, was induced 1.6 fold. Genes involved in
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cellular activation, vesicle formation, motility and modulation of the actin cytoskeleton were
also up regulated (KLRF1, STOM, S100A4, FEZ1, ARPC3 and TPM3P5). Cathepsin L (CTSL)
was the most down regulated gene by hsa-miR-99b. This protein is required for cleavage and
activation of perforin & granzyme B within lytic vesicles [32]. CD6 and IL-8 (interleukin-8)
Fig 3. Receiver operating curves of the four differentially expressedmiRNAwith confirmed expression changes after qRT-PCR analysis.
doi:10.1371/journal.pone.0150904.g003
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were also down regulated (1.6 and 1.5 fold respectively). Reduced expression of these genes is
associated with NK cell maturation following activation [33, 34]. Reduced expression was also
identified in genes involved in the autophagy, WNT and AKT signalling pathways (ULK1,
ATG2A, PMEPA1, DKK3, PDCD4).
To determine whether the genes regulated by hsa-miR-99b grouped to a specific functional
class, we conducted an overrepresentation analysis which identified a significant enrichment
for genes involved in processes and pathways of NK cell function, including cell activation,
immune system processes, and cellular response to stimulus (S3 Table).
Transfection of primary NK cells with pre-miR-330-3p compared to a nonsense control
produced only two changes; to SOD2 and MMP9 expression, both of which were down regu-
lated by 1.6 fold (S4 Table). SOD2 expression impairs normal T-cell differentiation and cellular
activation [35, 36] and reduced expression is associated impaired neutrophil effector function
[37]. MMP9 regulates NK cell cytotoxicity and lymphocyte motility [38, 39].
These results demonstrated that miRNAs expressed at increased levels in NK cells taken
from CFS/ME patients promote gene expression changes consistent with cellular activation but
reduced effector function.
Discussion
Current clinical diagnosis of CFS/ME is made based on well-defined clinical criteria [3–5, 40],
however diagnosis also includes a process of exclusion of other causes of fatigue which can
result in a prolonged time to diagnosis. Thus there is a real clinical need to identify diagnostic
biomarkers in CFS/ME. We set out to study the role of miRNA in patients with an established
diagnosis of CFS/ME, in order to determine whether these regulatory molecules were contrib-
uting to disease pathogenesis and could be candidate diagnostic biomarkers.
Fig 4. Four miRNA demonstrating differential expression by microarray and qRT-PCR tested by qRT-PCR in four cell populations. bars highlight
fold change error bars the 95% CI.
doi:10.1371/journal.pone.0150904.g004
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We identified over-expression of 34 miRNA not previously described in CFS/ME [41, 42] in
peripheral blood samples taken from CFS/ME patients by microarray. This analysis robustly
groups miRNA with coordinated expression (hsa-miR-107 and hsa-miR-103) and is highly
homogenous across samples. In common with other CFS/ME studies of gene expression the
miRNA profile did not separate CFS/ME patients from controls [7]. The study of Brenu and
colleagues (41) analysed plasma samples from CFS/ME patients and identified deregulation of
19 human miRNA. Of these 19, only 12 were represented in our array, of which 8 had a fold-
difference of1.5 in CFS/ME as compared with normals, but all had insignificant P values,
and so were not investigated further. The absence of concordance between the two studies is
unsurprising, as cellular and plasma miRNA profiles from the same individual demonstrate
limited overlap [43]; this limited overlap has been proposed to result from the fact that miRNA
are loaded into secreted vesicles with different efficiencies or the variable stability of different
miRNA in the extracellular environment [44]. The CFS/ME population exhibit a wide range of
clinical symptom scores supporting subgroups of disease which have been described elsewhere
[25] and may contribute to the incomplete resolution of samples in this analysis. This observa-
tion also would explain the poor correlation between clinical symptom score and miRNA
expression and would suggest that validation in an expanded patient cohort would be
desirable.
Confirmation of the array findings by qRT-PCR supported the up regulation of hsa-miR-
99b, hsa-miR-330-3p, hsa-miR-126 and hsa-miR-30c in CFS/ME PBMCs. The level of confir-
mation between the two methodologies is modest (R = -0.59) when compared to studies of
mRNA expression in CFS/ME [7, 25]. This discrepancy has been suggested to be due in part to
the differing methodologies employed [45], with fold changes below +/-2 fold [46–48] and low
abundance of transcript linked to poorer concordance between methods. This highlights a con-
sistent problem in miRNA studies as the cut-off commonly taken for miRNA gene expression
experiments is 1.5 fold change which may lead to exclusion of positive data [49].
The miRNA with increased expression in CFS/ME could potentially act as disease biomark-
ers which could be utilised to improve and expedite diagnosis. This has been previously
attempted in a number of studies identifying potential biomarkers in the serum [9], cytokine
expression [31], Dipeptidyl peptidase-4 (CD26) [50] and lymphocyte gene expression [6, 51,
52]. To determine whether the four up regulated miRNA were suitable markers to resolve CFS/
ME subjects from a matched control cohort, a ROC analysis was performed. This demon-
strated that all four markers could resolve patients from controls (AUC = 0.71–0.78) with a
comparable specificity to published studies. These miRNA may be specific to CFS/ME patients
exhibiting expression consistent with controls in fibromyalgia [53, 54] and depression [55, 56]
patients, two conditions with symptoms in common with CFS/ME. However, validation in
larger blinded cohorts of patients would need to be undertaken before the diagnostic utility of
the miRNA identified in this study could be fully explored.
Peripheral blood lymphocytes have been intensively examined in CFS/ME patients identify-
ing alterations in cytokine secretion and changes in cellular populations and activity [13, 57].
The cellular pathways and processes regulated by miRNA are frequently cell specific [58, 59].
To attempt to identify the leucocyte population contributing to altered miRNA expression in
CFS/ME, the four miRNA with increased expression were quantified in PBMC fractions from
a new patient cohort. Hsa-miR-126 demonstrated increased expression in monocytes.
Although to date a specific defect in monocyte activity has not been described in CFS/ME, hsa-
miR-126 has been demonstrated to down-regulate CRK protein expression. This protein inhib-
its cell invasion and migration [60] and has been demonstrated to control proliferation in den-
dritic cells [61], suggesting increased monocyte activity mediated by miRNA may be
contributing to the pathogenesis of CFS/ME.
MicroRNA Biomarkers in Chronic Fatigue Syndrome
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Hsa-miR-330-3p and hsa-miR-99b demonstrate increased expression in B cell and NK cell
populations. These miRNA have been associated with cancer, endometriosis, cell fate decisions
and angiogenesis [62–70]. Hsa-miR-99b has been demonstrated to target components of NF-
kB, mTOR and AKT signalling pathways [71]. mTOR signalling is crucial for normal prolifer-
ative, cytotoxic and cytokine effector functions in healthy NK cells [72] and normal BCR (B
cell receptor) signalling and proliferation [73] in B-cells. Increased hsa-miR-99b expression
regulating mTOR supports the reduction in effector function observed in NK cells in CFS/ME
patients seen in the literature [11, 13] and supports the deregulation of genes involved in B-cell
maturation and development identified in gene expression studies [74]. Hsa-miR-330-3p has
been demonstrated to regulate cellular motility by down regulating SP1 in prostate cancer cells
[75], and proliferation by reducing CDC42 levels in colorectal cancer [76].
Hsa-miR-30c does not exhibit altered expression in the cellular fractions analysed suggest-
ing the over-expression observed in the original PBMC cohort and may be cohort-specific.
This demonstrates the necessity for validation of findings in separate unrelated cohorts or
patients.
To study the effects of the altered miRNA expression identified in CFS/ME on cellular
mRNA, we elected to transfect the miRNA with the greatest magnitude of over expression
(hsa-miR-99b and hsa-miR-330-3p) into healthy NK cells, which are most consistently identi-
fied as functionally impaired in CFS/ME patients [11, 13, 14]. Interferon Gamma (IFN-γ) dem-
onstrated the greatest degree of altered expression in response to hsa-miR-99b introduction
with a 2.6 fold increase in expression. This gene encodes a cytokine secreted by NK cells with a
crucial role in anti-viral, anti-tumour and immune regulatory effects combined with promoting
NK cell activity [77]. IFN-γ has been measured in a number of studies in CFS/ME with variable
results. Increased mRNA in NK cells from CFS/ME patients has been demonstrated [13], sup-
ported by an increase in circulating IFN-γ secreting CD3- CD56+ NK cells described in CFS/
ME patients [78]. However plasma concentrations of IFN-γ were unchanged when analysed in
40 female CFS/ME patients and matched controls [31].
One consistent finding in CFS/ME patients is the reduction in the cytotoxic activity of NK
cells [11, 13, 14], frequently associated with an alteration in the level of components of cyto-
toxic granules notably granzyme and perforin [13, 14]. In this study Granzyme B (GZMB) was
significantly up regulated by hsa-miR-99b suggesting an enhanced cytotoxic capacity. However
CTSL (Cathepsin L) exhibited the greatest degree of down regulation by hsa-miR-99b. This
enzyme is required to process lytic granule components, granzyme and perforin from precur-
sor to active forms suggesting an explanation for the increased GZMB mRNA seen here and in
the literature leading to reduced effector function. This mechanism suggests an accumulation
of precursor proteins for GZMB and perforin in lytic vesicles with reduced cytotoxic function
which is supported by recent data which identified reduced NK cell cytotoxicity in CFS/ME
patients without an associated impairment in degranulation [78]. Over expression of hsa-miR-
99b and hsa-miR-330-3p induced a gene expression pattern consistent with NK cell activation
increasing IFN- γ expression and genes involved in cellular motility, vesicle formation and
modulation of the actin cytoskeleton (KLRF1, STOM, S100A4, FEZ1, ARPC3 and TPM3P5),
confirmed by over representation analysis. Activated NK cells in the peripheral blood of CFS/
ME patients have been postulated to result from incomplete resolution and control of viral
infection which is the most commonly cited trigger for onset of CFS/ME symptoms. This data
also demonstrates a molecular basis for the reduction in NK cytotoxicity seen in CFS/ME
patients mediated by miRNA, via direct down regulation of enzymes required for processing
cytotoxic vesicle components and down regulation of genes within Autophagy, WNT and AKT
pathways (ULK1, ATG2A, PMEPA1, DKK3, PDCD4) required for normal proliferation and
maturation of activated NK cells. Additional validation of the protein targets regulated by the
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identified miRNA would be desirable to fully define the miRNA mediated NK cell dysfunction
in CFS/ME.
The data presented identifies deregulation of miRNA expression in the peripheral blood
cells of CFS/ME patients which was confirmed in two patient cohorts in PBMCs and cellular
subsets and identifies four potential diagnostic biomarkers. Natural killer cells demonstrated
the greatest changes in miRNA expression with up regulation of hsa-miR-99b and hsa-miR-
330-3p. These findings are functionally consistent with current understanding of the pathogen-
esis of CFS/ME. The work presented here provides novel evidence for an altered NK cell activa-
tion pathway in CFS/ME involving hsa-miR-99b and suggests a mechanism for the reduced
effector function seen in CFS/ME which has not been demonstrated previously.
Materials and Methods
Ethical Approval
All participants gave informed written consent for the withdrawal of 25ml of blood to be tested
for gene expression analysis, clinical analysis by self-report questionnaire and storage of
plasma/serum. This study was approved by Wandsworth Research Ethics Committee
(Approval Number 05/Q0803/137).
Subject recruitment
CFS/ME subjects were recruited from two specialist CFS/ME centres located in Poole hospital,
Dorset (N = 15) and St Helier hospital (N = 20), London following diagnosis by a clinical spe-
cialist and the exclusion of other possible sources of fatigue. All CFS/ME subjects selected for
the study were diagnosed using the Fukuda clinical criteria for diagnosing CFS/ME [3]. These
subjects also fulfilled the Canadian criteria for diagnosis of CFS/ME [79]. Patients with psychi-
atric disease were excluded from the study using the Minnesota International Neuropsychiatric
Interview (MINI); all CFS/ME subjects included in this study were therefore free of major psy-
chiatric disease and drug or alcohol abuse. Average disease duration was 6.8 yrs.
Thirty healthy normal blood donors were recruited from the East Dorset National Blood
Service (NBS) and 20 volunteers working within St George’s hospital that responded to invita-
tions to take part in the study. Restrictions on donation to the NBS were used to maintain con-
sistency within this comparison group which have been published elsewhere [7]. For both CFS/
ME and control subject groups, individuals who smoked within the previous year, who abused
alcohol or other drugs, were currently taking (or were within 3 months of taking) antibiotics,
steroids, cytotoxic drugs or antidepressants were excluded from the study to remove any con-
founding factors that have been demonstrated to alter gene expression [80, 81]. Blood tests for
haematological, biochemical, and liver function revealed no abnormalities in all patients.
Clinical Data
Clinical data was collected from all participants in the form of five self-report questionnaires:
Chalder Fatigue Scale, Pittsburgh Sleep Quality Index, McGill Pain Questionnaire, SPHERE
and Medical Outcomes Survey—Short Form -36 (SF-36). These questionnaires have been
assessed for suitability in recording CFS/ME symptoms by the CDC CFS/ME working group
[82] and have provided evidence for defined groups of CFS/ME based on gene expression data
[24]. All parameters assessed demonstrated a significant difference (P>0.05 Students T-test)
from the healthy participants in both study populations with the exception of SF-36 segments
for mental health and role emotional which were similar between CFS and control groups.
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miRNA Bioarray
PBMCs were isolated in vaccutainer CPT Cell Preparation tubes with Sodium Citrate (BD bio-
sciences, NJ, USA) from 16ml of blood. RNA was extracted by Trizol and enriched for the
small RNA fraction (<40nt) using the Ambion Flash-PAGE system, prior to labelling and
hybridisation of mature RNA samples to Ambion Bioarray V1.0 which assays 385 miRNA per
sample. 15 CFS samples recruited from the Dorset CFS clinic were age and sex matched +/- 5
years 2:1 with 30 controls recruited in the same geographical location. Seven CFS samples were
run in duplicate, batching samples in groups of 14 with technical replicates run in separate
batches. Technical replicates demonstrated a high concordance R = 0.97 (+/- 0.03 SD).
Matched samples were run on the same array slide to minimise variation between slides. Arrays
were scanned using a Genetic Microsystems GMS 418 scanner with a laser intensity of 95%, at
range of gain settings to avoid saturation of array spots. Intensity values were generated using
Imagene V5.5 (BioDiscovery, USA) using automatic segmentation. Un-background corrected
median intensity values were corrected using Microarray valuation imp (MAVI) Pro 2.6.0 soft-
ware (MWG biotech AG Ebersburg, Germany), which conducts a linear regression analysis on
three gain scans of an array image to impute the values at the periphery of detection. Data was
then normalised by median scaling setting the median of each array to 100 and log transformed
(base10) adapted from [83]. A significant change in expression between groups was defined as
a fold change of1.5 between group means, taking P-values below 0.05 as significant after
Mann-Whitney U test and Benjamini and Hochberg FDR correction [84]. Gene expression
must also be present in 50% of the samples tested. Matched samples P100_1 and C261 failed
hybridisation and were excluded (GSE70371).
Quantitative Polymerase Chain reaction (qRT-PCR)
miRNA expression changes observed by microarray were validated by quantitative reverse
transcription qRT—PCR. cDNA was generated from 10 ng Total RNA with miRNA specific
primers using the Taqman reverse transcription kit (Applied biosystems). cDNA (1.33 μL) was
added to triplicate 20 μl PCR reactions with corresponding no-template and no-RT controls
for each reaction. Hsa-miR-16 was used as the endogenous control in PBMC samples, CD3
+ T-Cell, CD14+ Monocyte fractions. Hsa-let-7a was used for the endogenous control in CD19
+ B-cell and CD56+ NK cell experiments after validation of 8 putative endogenous controls
(hsa-miR-16, hsa-Let-7a, hsa-miR-106a, RNU6B, hsa-miR-154, hsa-miR-30e-3p and rno-miR-
336) for stability of expression using gNorm [85] and normfinder algorithms [86]. Reactions
were performed on the 7500 Fast real-time PCR system (Applied Biosystems) using the stan-
dard thermal cycler protocol. Average cT was generated from triplicate reactions with SD>0.5.
The change in expression of each target gene was calculated relative to the endogenous control
gene using the Relative quantification (RQ) method where RQ = 2−ΔΔCT. Fold change ratio
were calculated by diving groups means.
Statistical analysis
Statistical analysis of miRNA data was performed in Genespring V 7.3.1 (Agilent technologies,
USA) & Bead studio and Genespring V 10 for the mRNA array data. Pearson correlations and
ROC analysis were performed in Prism V5.03 and Excel. Clustering of gene expression values
was carried out in cluster V3.0, prior to visualising in TreeView V1.60. Similarity between miR-
NA’s and samples was determined using Euclidean distance; Average linkage was used to cal-
culate the distance between samples or miRNA.
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Gene Ontology
miRNA predicted targets and gene expression data were subjected to an over-representation
analysis using Panther gene classification software (www.pantherdb.org) to identify enrich-
ment for Pathways, Molecular function and Biological processes. Statistical significance was
assigned by binomial test comparing the number of genes highlighted in a particular pathway,
to a list of genes of the same size randomly selected from the genome and classified in the same
manner. Data with P-values> 0.01 were excluded.
Enrichment for cellular populations
PBMCs were isolated from blood samples and buffy coats by density gradient centrifugation.
Monocytes (CD14+), B-cells (CD19+), NK cells (CD56+) and T-cells (CD3+) were isolated
using Miltenyi Macs beads and columns sequentially labelling and positively selecting popula-
tions. RNA was isolated using trizol determining quality and quantity by nanodrop and Agilent
bioanalyser. NK cells for the functional target characterisation were isolated from healthy buffy
coats purchased from the NBS using the negative selection NK cell isolation kit II (Miltenyi
biotec).
Flow Cytometry
Cellular purity post enrichment was determined for each fraction by flow cytometry. For each
population 2.5x105 cells were labelled with 5μl of corresponding PE conjugated antibody incu-
bating at 4°C for 30 minutes. The following antibodies were used: CD19-PE (LT19), CD56-PE
(REA196), CD14-PE (TÜK4), CD3-PE (BW264/56), IgG1-PE and IgG2-P (miltenyi biotec).
Over expression of miRNA precursors in healthy NK cells
NK cells were transfected by electroporation using the Amaxa Human NK cell nucleofector kit
(Lonza) with 100nM of hsa-miR-99b, hsa-miR-330-3P or non-sense control precursors
(Ambion). These conditions generated the greatest reduction in PTK9 mRNA of 71% after
hsa-miR-1 transfection at 24 hours incubation (Pre-miR miRNA starter kit, Ambion) when
assessed by qPCR (data not shown). 2x106 transfected NK cells were incubated at 37°C with
5% CO2 in RPMI 1640 cell culture media supplemented with 10% Fetal bovine serum (Invitro-
gen), 100μg/ml Streptomycin, 100U/ml penicillin, 2mM GlutaMAX (Invitrogen) and 200 U/
ml IL-2 (Miltenyi). Triplicate transfections were prepared for each condition. 24 hours post
transfection cells were washed twice with PBS and RNA isolated with Trizol.
mRNA Analysis by Illumina HT12 V3 bead array
The Illumina TotalPrep RNA Amplification kit (Ambion PNIL1791M) was used to generate
fragmented biotin labelled cRNA for hybridisation to Illumina HT12 V3 bead arrays. 750ng
RNA was prepared for each of the three transfection conditions. Bead chips were scanned on
the iScan scanner (Illumina San Diego, CA). Prior to the detection of differentially expressed
genes the data was locally background corrected for each bead, averages were generated for
beads with the same probe and outliers removed. This is an automatic correction performed by
the iScan software (Illumina, San Diego, CA). The data was quality assessed in Genome studio
v1.1.1 (Illumina, San Diego, CA). The bead array data was imported into Genespring V10 for
normalisation and detection of differentially expressed genes. Quantile normalisation was used
combined with an additional normalisation to the non-sense transfected samples which repre-
sents the baseline expression for the experiment. The data was filtered to remove probes where
detection of an expressed signal was incomplete in the biological replicates. The difference in
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expression between target gene transfection and non-sense control was calculated by subtract-
ing the log transformed group means for each group to generate a fold change ratio. Genes
were selected for further analysis if they demonstrated a P-value after T-testing of0.05 and
passed the fold change cut-off of a change in expression over 1.5 fold (GSE69555).
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